PTC Therapeutics

PTC Therapeutics Grants Inducement Awards to 13 New Hires

Image
PTC Therapeutics Grants Inducement Awards to 13 New Hires

Warren – October 31, 2026 -- PTC Therapeutics (NASDAQ: PTCT) granted stock options on 9,620 shares and 11,535 restricted stock units to 13 new employees, with the options struck at $63.02 per share.

Compensation Committee approved the grants on Oct. 28 under Nasdaq's inducement exception

The awards were made under the Nasdaq inducement grant exception, Listing Rule 5635(c)(4). PTC describes them as material to each employee's decision to accept employment. The options are non-statutory.

Option exercise price is set at the $63.02 closing price on the grant date

The exercise price matches PTC's closing share price on Oct. 28, 2026. Each option has a 10-year term and vests over four years. A 25% tranche vests on the first anniversary of the employee's hire date. After that, 6.25% of the original share count vests at the end of each three-month period until fully vested. Vesting depends on continued service.

PTC Therapeutics Lifts 2026 Guidance as Q3 Product Revenue Doubles

Image
PTC Therapeutics Lifts 2026 Guidance as Q3 Product Revenue Doubles

Warren – October 30, 2026 -- PTC Therapeutics (NASDAQ: PTCT) reported third-quarter 2026 total revenue of $358 million and raised its full-year product revenue guidance to $960 million to $990 million, up from $850 million to $950 million. Total revenue guidance for 2026 now stands at $1.29 billion to $1.32 billion.

Product revenue more than doubles on Sephience launch

Net product revenue across the commercial portfolio reached $275.9 million, against $131.0 million in the third quarter of 2025. Net product and royalty revenue combined totaled $357.6 million, compared with $201.7 million a year earlier.

Sephience (sepiapterin) generated $181.9 million, up 20% from the second quarter. US sales were $145 million and ex-US sales $37 million. More than 2,000 patients were on therapy worldwide as of September 30. CEO Matthew Klein said the launch has been a success by all measures and that PTC is on track to reach cash flow breakeven this year.

PTC Therapeutics Closes ST-920 Fabry Gene Therapy Acquisition

Warren, N.J. – September 22, 2026 -- PTC Therapeutics, Inc. (NASDAQ: PTCT) has completed its acquisition of ST-920, a BLA-stage, one-time AAV gene therapy for Fabry disease, from Sangamo Therapeutics, Inc.

PTC targets Q4 2026 completion of rolling BLA submission for accelerated approval

The company confirmed that a rolling Biologics License Application submission to the FDA seeking accelerated approval of ST-920, also known as isaralgagene civaparvovec, is expected to be completed in the fourth quarter of 2026.

PTC Therapeutics Names Morgan Stanley Biotech Banking Pioneer Jessica Chutter to Board of Directors

Image

SHERIDAN, WYOMING - April 14, 2026 - PTC Therapeutics has appointed Jessica Chutter to its Board of Directors, adding a seasoned biotechnology investment banker who built and led Morgan Stanley's biotechnology franchise over an extensive tenure at the firm. The appointment brings capital markets expertise directly into PTC's governance structure at a time when the company operates multiple approved therapies across the U.S. and international markets and continues to invest in a diversified rare disease pipeline. Chutter is described by the company as a highly accomplished biotechnology investment banker with an extensive list of achievements. The board addition reinforces PTC's strategic focus on commercialization and financial positioning in specialty pharma.